ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,999.79
-0.08%
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs Yen
155.724
0.21%
Brent Oil
84.17
0.26%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Akebia Therapeutics Inc (AKBA)

  7. Akebia Therapeutics Inc (AKBA) ニュース

AKBA

Akebia Therapeutics (AKBA)

Akebia Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AKBA
日付受信時刻ニュースソース見出しコード企業名
2024/05/1006 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/05/0920 : 05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKBAAkebia Therapeutics Inc
2024/05/0920 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKBAAkebia Therapeutics Inc
2024/05/0920 : 00PR Newswire (US)Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
2024/05/0221 : 30PR Newswire (US)Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
2024/05/0205 : 05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
2024/04/0305 : 05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
2024/03/2809 : 26PR Newswire (US)Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/1505 : 15PR Newswire (US)Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/1206 : 05PR Newswire (US)Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0207 : 49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0207 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0207 : 47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0207 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0206 : 05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0108 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0108 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0108 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0108 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0106 : 32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0106 : 28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/03/0106 : 27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/2808 : 19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/2808 : 16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/2808 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/2808 : 11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/1322 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/0306 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/0306 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
2024/02/0306 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKBA

最近閲覧した銘柄

CCOM
US30
US 30
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
NASDAQ
AMZN
Amazon.com
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
VZ
Verizon Communications
COIN
SOLUSD
Solana
FX
USDEUR
US Dollar vs Euro
CCOM
SILVER
SILVER
SPI
SP500
S&P 500
NYSE
MRK
Merck
NASDAQ
TSLA
Tesla
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有